HOOK — Hookipa Pharma Share Price
Last trade - 00:00- $10.25m
- -$29.43m
- $43.95m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.2 | ||
| Price to Tang. Book | 0.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -88.88% | ||
| Return on Equity | -61.68% | ||
| Operating Margin | -117.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 19.58 | 18.45 | 14.25 | 20.13 | 43.95 | 19.25 | 1 | 29.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Directors
- Jan van de Winkel NEC (60)
- Joern Aldag CEO (62)
- Reinhard Kandera CFO (51)
- Klaus Orlinger EVP (43)
- Roman Necina CTO (53)
- Christine Baker OTH (56)
- Igor Matushansky OTH (48)
- David Kaufman IND (48)
- Michael Kelly IND (64)
- Christoph Lengauer IND (56)
- Julie O Neill IND (55)
- Jean-Charles Soria IND (50)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 15th, 2017
- Public Since
- April 18th, 2019
- No. of Shareholders
- 1
- No. of Employees
- 82
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 12,059,039
- Address
- 350 Fifth Avenue, 72Nd Floor, Suite 7240, NEW YORK, 10118
- Web
- https://www.hookipapharma.com/
- Phone
- Auditors
- PwC Wirtschaftsprufung Gmbh
Latest News for HOOK
Upcoming Events for HOOK
Q1 2025 HOOKIPA Pharma Inc Earnings Release
HOOKIPA Pharma Inc Annual Shareholders Meeting
Q2 2025 HOOKIPA Pharma Inc Earnings Release
Similar to HOOK
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 21:09 UTC, shares in Hookipa Pharma are trading at $0.85. This share price information is delayed by 15 minutes.
Shares in Hookipa Pharma last closed at $0.85 and the price had moved by -89.46% over the past 365 days. In terms of relative price strength the Hookipa Pharma share price has underperformed the S&P500 Index by -90.27% over the past year.
The overall consensus recommendation for Hookipa Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreHookipa Pharma does not currently pay a dividend.
Hookipa Pharma does not currently pay a dividend.
Hookipa Pharma does not currently pay a dividend.
To buy shares in Hookipa Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.85, shares in Hookipa Pharma had a market capitalisation of $10.25m.
Here are the trading details for Hookipa Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HOOK
Based on an overall assessment of its quality, value and momentum Hookipa Pharma is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Hookipa Pharma is $24.75. That is 2811.76% above the last closing price of $0.85.
Analysts covering Hookipa Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$2.53 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hookipa Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -76.3%.
As of the last closing price of $0.85, shares in Hookipa Pharma were trading -72.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hookipa Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hookipa Pharma's management team is headed by:
- Jan van de Winkel - NEC
- Joern Aldag - CEO
- Reinhard Kandera - CFO
- Klaus Orlinger - EVP
- Roman Necina - CTO
- Christine Baker - OTH
- Igor Matushansky - OTH
- David Kaufman - IND
- Michael Kelly - IND
- Christoph Lengauer - IND
- Julie O Neill - IND
- Jean-Charles Soria - IND